BioWiki

プロスタグランジン

アラキドン酸(20個の炭素をもつ不飽和脂肪酸)からシクロオキシゲナーゼによる反応を経て得られる化合物。非常に多くの生理的な現象にかかわっている。 (MeSH: 68011453)

プロスタグランジン エンドペルオキシド

アラキドン酸からプロスタグランジン群やトロンボキサンを生合成する前駆体 これらは生理学的にも活性な化合物で、血管や気道平滑筋、血小板凝集などに影響を与える。もっとも良く見られるのはプロスタグランジンH2である。

名前Prostaglandin H2
PubChem image 25245222

Prostaglandin H2 - アラキドン酸からシクロオキシゲナーゼによる反応で得られる環状エンドペルオキシド中間体で、ここからさらに一連の酵素反応によって2種類のプロスタグランジンへ変換される。(MeSH: 68044262)

プロスタグランジンA

名前PGA1
PubChem image 5281912

名前PGA2
PubChem image 5280880

プロスタグランジンD

名前PGD2
PubChem image 448457

プロスタグランジンF

名前6-Ketoprostaglandin F1 alpha
PubChem image 5283044
Epoprostenol(プロスタグランジンI)の加水分解物

プロスタグランジンI

名前prostaglandin I2,Epoprostenol,PGI2
PubChem image 5280427

Prostaglandins - MeSH

(temporary memo)

  • Prostaglandin Endoperoxides
    Precursors in the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. They are physiologically active compounds, having effect on vascular and airway smooth muscles, platelet aggregation, etc. Year introduced: 1978
    • Prostaglandins G
      A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. Most frequently encountered member of this group is the prostaglandin G2. Year introduced: 1991(1978)
    • Prostaglandins H+
      A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin H2. Year introduced: 1991(1978)
  • Prostaglandins A
    (13E,15S)-15-Hydroxy-9-oxoprosta-10,13-dien-1-oic acid (PGA(1)); (5Z,13E,15S)-15-hydroxy-9-oxoprosta-5,10,13-trien-1-oic acid (PGA(2)); (5Z,13E,15S,17Z)-15-hydroxy-9-oxoprosta-5,10,13,17-tetraen-1-oic acid (PGA(3)). A group of naturally occurring secondary prostaglandins derived from PGE; PGA(1) and PGA(2) as well as their 19-hydroxy derivatives are found in many organs and tissues. Year introduced: 1975
  • Prostaglandins B
    Physiologically active prostaglandins found in many tissues and organs. They are potent pressor substances and have many other physiological activities. Year introduced: 1991(1978)
  • Prostaglandins D
    Physiologically active prostaglandins found in many tissues and organs. They show pressor activity, are mediators of inflammation, and have potential antithrombotic effects. Year introduced: 1984(1978)
    • Prostaglandin D2
      The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. Year introduced: 1989
  • Prostaglandins E
    (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. Year introduced: 1975
    • Dinoprostone
      A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. Year introduced: 1989
  • Prostaglandins F
    (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. Year introduced: 1975
    • 6-Ketoprostaglandin F1 alpha
      The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. Year introduced: 1982
    • Dinoprost
      A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.Year introduced: 1989
  • Prostaglandins I
    A class of cyclic prostaglandins that contain the 6,9-epoxy bond. Endogenous members of this family are biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES. Year introduced: 2004
    • Epoprostenol
      A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Year introduced: 1991(1978)

Links